A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution
- Registration Number
- NCT04132570
- Lead Sponsor
- Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
- Brief Summary
The primary objective of this study is to assess the effectiveness of intranasal budesonide aqueous spray 256 microgram (mcg)/day for treatment of rhinitis symptoms during times of high airborne pollution.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 206
- Self-reported rhinitis symptoms triggered or worsened by airborne pollution, with agreement by physician at screening visit
- Participant must have moderate to severe rhinitis symptoms as defined by a 24-hour reflective total nasal symptom score (rTNSS) of at least 5 (maximum 9), based on three individual nasal symptom scores (nasal obstruction, secretion/runny nose, itching/sneezing) at the time of the screening visit, including at least one individual symptom score of 3 for nasal obstruction and/or secretion/runny nose
- Regularly have outdoor exposure during a normal week in the winter season, including greater than or equal to (>=) 1 hour on most days. Outdoor exposure may include commuting activities (such as walking/bicycle/auto/bus/city metro train travel), outdoor work, exercise, shopping, or other outdoor activities
- A woman of childbearing potential must have a negative urine pregnancy test (beta human chorionic gonadotropin [beta hCG]) at screening and agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 30 days after the last administration of study agent
- Male participants who are not surgically sterilized and are heterosexually active with a woman of childbearing potential, must agree to use a barrier method of contraception (example condom with spermicidal foam/gel/film/cream/suppository) and to not donate sperm during the study and for 30 days after last receiving study agent. Note that barrier methods must also be used in all male subjects sexually active with pregnant partners for at least 30 days after last study agent administration
- Participants can understand the questionnaires and are able to complete the questionnaires in the format provided
- Reside in the same city as the study site that they will be visiting
- History of hypersensitivity to budesonide or any ingredients in the formulation
- Upper respiratory infection within 2 weeks of screening visit
- Current symptoms consistent with diagnosis of common cold, influenza, or other respiratory infection according to physician evaluation
- Using of N-95 masks days during with high airborne pollution
- Presence of nasal polyps or deviated septum as confirmed by nasal endoscopy
- History of nasal surgery
- Presence of chronic or active rhinosinusitis or sinusitis
- Systemic, intranasal or topical corticosteroid use within 1 month, intranasal or systemic decongestants within 3 days, antihistamine use within 1 week, intranasal cromolyn within 2 weeks, leukotriene use within 1 month, or immunotherapy within 2 years of screening visit
- Asthma, with the exception of mild intermittent asthma not requiring medication
- Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (example compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo (Treatment B) Placebo Participants will self-administer 2 nasal sprays of matching placebo in each nostril once daily (in the morning) up to 10 +\\- 3 Days. Budesonide 256 mcg per Day (Treatment A) Budesonide Participants will self-administer 2 nasal sprays of Budesonide (64 microgram \[mcg\]/spray) in each nostril once daily (every morning) up to 10 +\\- 3 Days.
- Primary Outcome Measures
Name Time Method Mean Change from Baseline in 24-hour Reflective Total Nasal Symptom Score (rTNSS) Baseline up to 10 days (24 hours each day) Mean change from baseline in 24-hour reflective total nasal symptom score (rTNSS) calculated as the sum of the participant-assessed 24-hour reflective severity ratings for three individual nasal symptom scores (nasal obstruction, secretion/runny nose, itching/sneezing) averaged over the first 10-day treatment period. Baseline value will be a single 24-hour rTNSS recorded on the no-treatment evening following the baseline visit. The individual nasal symptom scores will be recorded at home by participants in their diary on a four point scale (from 0=none to 3=severe). The sum of the individual scores will form the 24-hour rTNSS.
- Secondary Outcome Measures
Name Time Method Subject Global Impression of Change (SGIC) at the Final Efficacy Assessment Day 10 (+/-3) Participant will rate Global Impression of Change at Final Efficacy Assessment on a 5-point scale from 0 (symptoms were aggravated) to 4 (total control over symptoms). An increase in score indicates the improvement in condition.
Mean Change from Baseline in Individual Nasal Symptoms Scores (NSS) Baseline to 10 days (24 hours each day) Mean Change from Baseline in individual NSS for nasal obstruction, secretion/runny nose, and itching/sneezing averaged over the first 10-day treatment period will be reported using 4-point scale from 0=None, 1=Mild, 2=Moderate, or 3=Severe.
Mean Change from Baseline in 24-hour Reflective Individual non-Nasal Symptoms Score (Cough and Post-Nasal Drip) Baseline to 10 days (24 hours each day) Mean Change from Baseline in 24-hour reflective Individual non-Nasal Symptoms Score for cough and post-nasal drip averaged over the first 10-day treatment period, using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe condition.
Number of Participants With Adverse Events (AEs) as a Measure of Safety Up to Day 10 +/- 3 days or up to 30 days after the last day of the study treatment period (Day 10) An AE is any untoward medical occurrence in a clinical study subject administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.
Trial Locations
- Locations (6)
Beijing Tongren Hospital, Cmu
π¨π³Beijing, Beijing, China
The No.2 Hospital of Baoding
π¨π³Baoding, Hebei, China
Cangzhou Center Hospital
π¨π³Cangzhou, Hebei, China
The Second Hospital to Hebei Medical University
π¨π³Shijiazhuang, Hebei, China
Shandong provincial hospital
π¨π³Jinan, Shandong, China
The No.2 People'S Hospital Og Weifang
π¨π³Weifang, Shandong, China